Evidence map›Paper›PMID 38371088›Full record

ReviewCureus2024

Revolutionizing Cancer Care: Advances in Carbon-Based Materials for Diagnosis and Treatment.

Muhammad Zubair Khan, Danial Tahir, Muhammad Asim, Muhammad Israr, Ali Haider, Dan Dan Xu

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 5 countries.

Muhammad Zubair KhanInternal Medicine, Ayub Teaching Hospital, Abbottabad, PAK.
Danial TahirInternal Medicine, Nazareth Hospital, Philadelphia, USA.
Muhammad AsimInternal Medicine, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, GBR.
Muhammad IsrarBiological Sciences, Abasyn University, Islamabad, PAK.
Ali HaiderDepartment of Allied Health Sciences, The University of Lahore, Gujrat Campus, Gujrat, PAK.
Dan Dan XuIntegrative Medicine, Shandong University of Traditional Chinese Medicine, Jinan, CHN.
Abasyn University · PKAbbott (Germany) · DEAyub Medical College · PKNHS Lothian · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer involves intricate pathological mechanisms marked by complexities such as cytotoxicity, drug resistance, stem cell proliferation, and inadequate specificity in current chemotherapy approaches. Cancer therapy has embraced diverse nanomaterials renowned for their unique magnetic, electrical, and optical properties to address these challenges. Despite the expanding corpus of knowledge in this area, there has been less advancement in approving nano drugs for use in clinical settings. Nanotechnology, and more especially the development of intelligent nanomaterials, has had a profound impact on cancer research and treatment in recent years. Due to their large surface area, nanoparticles can adeptly encapsulate diverse compounds. Furthermore, the modification of nanoparticles is achievable through a broad spectrum of bio-based substrates, including DNA, aptamers, RNA, and antibodies. This functionalization substantially enhances their theranostic capabilities. Nanomaterials originating from biological sources outperform their conventionally created counterparts, offering advantages such as reduced toxicity, lower manufacturing costs, and enhanced efficiency. This review uses carbon nanomaterials, including graphene-based materials, carbon nanotubes (CNTs) based nanomaterials, and carbon quantum dots (CQDs), to give a complete overview of various methods used in cancer theranostics. We also discussed their advantages and limitations in cancer diagnosis and treatment settings. Carbon nanomaterials might significantly improve cancer theranostics and pave the way for fresh tumor diagnosis and treatment approaches. More study is needed to determine whether using nano-carriers for targeted medicine delivery may increase material utilization. More insight is required to explore the correlation between heightened cytotoxicity and retention resulting from increased permeability.

Indexed as

cancer carecancer diagnosiscancer therapycancer treatmentcarbon-based materialscarbon quantum dotschemotherapynanomaterialsnanotechnology

Identifiers

PMID38371088
PMCPMC10874252
OpenAlexW4390971658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.